Evaluating Lemborexant for Delayed Sleep Phase Syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the effectiveness of Lemborexant in reducing sleep onset latency in patients diagnosed with Delayed Sleep Phase Syndrome (DSPS). Participants will receive either Lemborexant or a placebo nightly for two years, with their sleep patterns monitored through sleep logs and actigraphy. The study will differentiate between two phenotypes of DSPS to better understand treatment responses. The goal is to determine if Lemborexant can improve sleep quality and daytime functioning for individuals affected by this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18 years of age or older.
2. Diagnosed with delayed sleep phase syndrome (DSPS) meaning that:

   1. Sleep is delayed by two hours or more beyond what is considered an acceptable or conventional bedtime for the subject (their desired bedtime).
   2. Subjects not able to fall asleep if trying to sleep before the later bedtime;
   3. This is interfering with their wishes/having social impact.
3. Concomitant medications will be allowed, though dosages will be required to remain fixed throughout participation in the study.
4. The participant also needs to be willing and able to comply with all aspects of the protocol.

Exclusion Criteria:

1. Clinically significant depression (PHQ-9 score of 10 or more), anxiety disorder (GAD-7 score of 10 or more), substance use disorder, any other sleep disorder (assessed by the Alliance Sleep Questionnaire- ASQ), or any medical disorder/therapy that could interfere with the trial (this will be verified through interview and analysis of the ASQ).
2. Use of medications with significant effects on sleep-wake function (insomnia therapies, stimulants)- unless they are discontinued at least 5 half-lives prior to study participation. Non-sedative antidepressants or SSRI will be allowed if at a stable dose in the absence of concomitant severe depression or severe anxiety.
3. Use of CYP3A inhibitors and CYP3A inducers, at least 1 week (or five half-lives, whichever is longer) prior to the first day of the baseline phase.
4. Pregnancy (verified by urine pregnancy test on visits 1, 2, and 3) or plan to become pregnant in the next 3 months or currently breastfeeding.
5. Shift workers or subjects working unusual hours.
6. Any risk of suicide within 6 months of screening period or throughout the trial (accessed by the Investigator and by the C-SSRS questionnaire).
7. Transmeridian travel across more than 3 time zones 4 weeks prior to the screening phase.
8. Transmeridian travel across more than 2 time zones during this trial (including the screening phase).
9. Having a positive drug test or being unwilling to refrain from using illegal drugs or marijuana during this trial.
10. Any clinically abnormal symptom or organ impairment found by medical history at Screening or Baseline and physical examinations, vital signs, ECG findings, or laboratory test results that require medical treatment.
11. Impaired liver function (values for enzymes aspartate transaminase (AST) and alanine transaminase (ALT) \> 1.5 times the Upper Limit of Normal).
12. Known to be human immunodeficiency virus positive.
13. Has a QT interval corrected using Fridericia's formula interval (QTcF interval) \>450 ms demonstrated on repeated ECGs (repeated only if initial ECG showed corrected QT interval (QTc) \>450 ms) at Screening or Baseline.

Where it's running

• University of California San Francisco
  San Francisco, California, United States Recruiting
• Stanford Univeristy
  Redwood City, California, United States Completed

Study contacts

• Principal investigator: Emmanuel Mignot, MD, PhD — Stanford University

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding Delayed Sleep Wake Phase Disorder

  This study is trying to understand what causes delayed sleep wake phase disorder by comparing people with the condition to healthy individuals and looking at their sleep patterns, light exposure, and blood sugar levels.

  Recruiting at 2 sites University of Colorado, Boulder · Boulder, Colorado and 1 other locations · NCT06471374

• A digital tool to help decide about an ICD

  We’re testing a patient-friendly online aid to help people with advanced heart failure decide whether an implantable cardioverter-defibrillator (ICD) is right for them.

  Recruiting at 2 sites Stanford University · San Francisco, California and 1 other locations · NCT07913204

• Wise Interventions to Boost Pediatric Weight Control

  This study tests whether adding two quick social-psychology activities (growth mindset and self-affirmation) to a family-based weight management program helps 10–15 year-olds with obesity achieve better BMI outcomes over 12 months.

  Recruiting Stanford University · Stanford, California · NCT07839832

• Reducing Chronic Pain After Cesarean Delivery

  A single-session pain-relief class called Empowered Relief is tested alongside standard postpartum care to see if it helps women who have ongoing pain after cesarean delivery.

  Recruiting Stanford University · Palo Alto, California · NCT07799883

• Human-created animated art vs AI-created art: does it change how you feel right away?

  This online trial tests whether watching a human-made animated art film or an AI-made one, or doing nothing, quickly changes mood or sense of connection in U.S. adults.

  Recruiting Stanford University · Palo Alto, California and 1 other locations · NCT07740148

• SMILE in one eye vs Ray tracing-guided LASIK in the fellow eye

  This study tests two laser vision correction methods—SMILE in one eye and ray-tracing guided LASIK in the other eye—to see which provides better vision and quality of life for adults with myopia and astigmatism.

  Recruiting Phase 4 Stanford University · Palo Alto, California · NCT07721714

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.